Immunome Stock Market Value
| IMNM Stock | USD 9.82 0.40 4.25% |
| Symbol | Immunome |
Immunome Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunome 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunome's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunome.
| 08/25/2024 |
| 11/23/2024 |
If you would invest 0.00 in Immunome on August 25, 2024 and sell it all today you would earn a total of 0.00 from holding Immunome or generate 0.0% return on investment in Immunome over 90 days. Immunome is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious di... More
Immunome Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunome's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunome upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 21.66 | |||
| Value At Risk | (7.21) | |||
| Potential Upside | 5.97 |
Immunome Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunome's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunome's standard deviation. In reality, there are many statistical measures that can use Immunome historical prices to predict the future Immunome's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.16) | |||
| Treynor Ratio | (0.25) |
Immunome Backtested Returns
Immunome holds Efficiency (Sharpe) Ratio of -0.16, which attests that the entity had a -0.16% return per unit of risk over the last 3 months. Immunome exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Immunome's Risk Adjusted Performance of (0.09), market risk adjusted performance of (0.24), and Standard Deviation of 4.01 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.12, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunome will likely underperform. At this point, Immunome has a negative expected return of -0.64%. Please make sure to check out Immunome's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Immunome performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.68 |
Good predictability
Immunome has good predictability. Overlapping area represents the amount of predictability between Immunome time series from 25th of August 2024 to 9th of October 2024 and 9th of October 2024 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunome price movement. The serial correlation of 0.68 indicates that around 68.0% of current Immunome price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 1.19 |
Immunome lagged returns against current returns
Autocorrelation, which is Immunome stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Immunome's stock expected returns. We can calculate the autocorrelation of Immunome returns to help us make a trade decision. For example, suppose you find that Immunome has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Immunome regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Immunome stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Immunome stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Immunome stock over time.
Current vs Lagged Prices |
| Timeline |
Immunome Lagged Returns
When evaluating Immunome's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Immunome stock have on its future price. Immunome autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Immunome autocorrelation shows the relationship between Immunome stock current value and its past values and can show if there is a momentum factor associated with investing in Immunome.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunome Correlation, Immunome Volatility and Immunome Alpha and Beta module to complement your research on Immunome. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Immunome technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.